A recent study developed TF-chimeric antigen receptor natural killer (NK) cells that effectively target TF-overexpressing triple-negative breast cancer cells to decrease tumor growth without significant systemic adverse effects (109). This evidence concerns the gene TF and triple-negative breast carcinoma.